Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.
2.

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, Beckers A, Fonteyne V, Van der Eecken K, De Bruycker A, Paul J, Gramme P, Ost P.

World J Urol. 2018 Dec 21. doi: 10.1007/s00345-018-2609-8. [Epub ahead of print]

PMID:
30578441
3.

The biology of prostate cancer metastases: does oligo differ from polymetastatic?

Sonpavde G.

Curr Opin Urol. 2017 Nov;27(6):542-546. doi: 10.1097/MOU.0000000000000434. Review.

PMID:
28786848
4.

The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.

Kucharczyk MJ, Gravis G, Niazi T.

Eur Urol Focus. 2019 Mar;5(2):117-118. doi: 10.1016/j.euf.2018.11.011. Epub 2018 Dec 4.

PMID:
30527643
5.

Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.

Barzilai O, Versteeg AL, Sahgal A, Rhines LD, Bilsky MH, Sciubba DM, Schuster JM, Weber MH, Pal Varga P, Boriani S, Bettegowda C, Fehlings MG, Yamada Y, Clarke MJ, Arnold PM, Gokaslan ZL, Fisher CG, Laufer I, The Ao Spine Knowledge Forum Tumor.

Cancer. 2019 Mar 1;125(5):770-778. doi: 10.1002/cncr.31870. Epub 2018 Nov 29.

PMID:
30489634
6.

Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.

Pasoglou V, Michoux N, Van Damme J, Van Nieuwenhove S, Halut M, Triqueneaux P, Tombal B, Lecouvet FE.

World J Urol. 2019 Mar 2. doi: 10.1007/s00345-019-02700-2. [Epub ahead of print]

PMID:
30826887
7.

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.

Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, Kramer G, Lievens Y, Lopci E, Pasquier D, Petersen LJ, Talbot JN, Zacho H, Tombal B, deSouza NM.

Lancet Oncol. 2018 Oct;19(10):e534-e545. doi: 10.1016/S1470-2045(18)30571-0. Epub 2018 Oct 1. Review.

PMID:
30303127
8.

Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.

Xu LM, Cheng C, Kang M, Luo J, Gong LL, Pang QS, Wang J, Yuan ZY, Zhao LJ, Wang P.

Sci Rep. 2017 Aug 23;7(1):9255. doi: 10.1038/s41598-017-09775-0.

9.

Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.

Sun Z, Zhou S, Tang J, Ye T, Li J, Liu D, Zhou J, Wang J, Rosie Xing H.

EBioMedicine. 2018 Nov;37:47-55. doi: 10.1016/j.ebiom.2018.10.002. Epub 2018 Oct 6.

10.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Joice GA, Rowe SP, Pienta KJ, Gorin MA.

Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449. Review.

PMID:
28863016
11.

A multicentre prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution, compared to standard imaging.

McCarthy M, Francis R, Tang C, Watts J, Campbell A.

Int J Radiat Oncol Biol Phys. 2019 Mar 16. pii: S0360-3016(19)30370-0. doi: 10.1016/j.ijrobp.2019.03.014. [Epub ahead of print]

PMID:
30890448
12.

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A.

World J Urol. 2019 Jan 31. doi: 10.1007/s00345-019-02652-7. [Epub ahead of print]

PMID:
30706122
13.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

14.

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

Clement JM, Sweeney CJ.

J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3. Review.

PMID:
28045610
15.

[Definitions of oligometastatic disease and new treatment concepts].

Kissel M, Helou J, Thariat J.

Bull Cancer. 2018 Jul - Aug;105(7-8):696-706. doi: 10.1016/j.bulcan.2018.04.012. Epub 2018 Jun 20. Review. French.

PMID:
29935914
16.

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.

Azzam G, Lanciano R, Arrigo S, Lamond J, Ding W, Yang J, Hanlon A, Good M, Brady L.

Front Oncol. 2015 May 5;5:101. doi: 10.3389/fonc.2015.00101. eCollection 2015.

17.

Chemotherapy for oligometastatic prostate cancer.

Dorff TB, Sweeney CJ.

Curr Opin Urol. 2017 Nov;27(6):553-558. doi: 10.1097/MOU.0000000000000446. Review.

PMID:
28817399
18.

Oligometastasis and oligo-recurrence: more than a mirage.

Huang F, Wu G, Yang K.

Radiat Oncol. 2014 Oct 31;9:230. doi: 10.1186/s13014-014-0230-6. Review.

19.

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.

Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR.

Clin Exp Metastasis. 2014 Aug;31(6):735-48. doi: 10.1007/s10585-014-9664-3. Epub 2014 Jun 27. Review.

20.

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer.

Miura Y, Horie S.

ESMO Open. 2019 Mar 12;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471. eCollection 2019. Review.

Supplemental Content

Support Center